% | $
Quotes you view appear here for quick access.

OXiGENE, Inc. Message Board

  • vukken99 vukken99 Sep 15, 2010 9:46 AM Flag

    The preliminary data with lung cancer with zybrestat was positive!

    Well I am planning to accumulate this stock daily or weekly...

    I foresee with positive lung ca data....there will be a very nice gain....

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Mid, we have always been in agreement with what we hope/think will happen with Oxigene when it's all said and done. You just don't understand how a "true" long can be frustrated with the current position we find ourselves in and therefor I must be a paid basher and/or have some ulterior motive. In fairness I guess I don't understand your continuous optimism, but in the end our goals/hopes are one in the same.

    • The Antisoma/Novartis deal was $70M upfront!

    • See what happened to Dynavax (DVAX) in December 2008. The stock was trading at $0.26 and the company signed a deal for only 10M upfront. Just two days later, the stock hit an intraday high of $2.60, exactly a ten-bagger!

    • Wow, East! Almost pumping! Did not recognize you! ;-) But we are in agreement! Oxigene must have a partner to run phase III in NCSLC and Ovarian. But that has been the case from the beginning. I have a slide from 2003 with the long term goals.

      As I see it we have some different partnering options:

      Ophthalmology! Oxigene has stated several times that this is subject to out licensing!
      CA4P Oncology! Oxigene stated in the last cc that they are conducting discussion with several parties in different stages.
      Oxi4503, Not been mentioned in partnering. I think Oxigene will try to keep this in house if they can!
      All indications deal, not been discussed but you never know!

      Regardless the outcome, any deal will send us sky high!

    • It will move with Lung cancer data....

      BIG PHarma needs new patents

      Also, it is wrong since for thyroid cancer approval
      FDA gave fast track status and they can get approved with strong phase II and III results
      due to lack of effective treatments for this type of cancers currently!

      REad the press releases it tells it all!

    • The stock will not make any sustainable and meaningful gain until they sign a partnership. If they can't sign a decent partner deal with good phase 2 Ovarian, ATC and Lung data, we are S^^& out luck and it's over, although I don't believe that will be the case

      • 1 Reply to east21052000
      • Partnership isn't the only way out, money via private, stock dilution or other means could be raised to proceed with further trials. If they do it on their own and end results are able to go fda route then Other companies will be banging at the door. IF they do it alone = more profit for share holders in the long run.

        I agree that upcoming data is good enough deal will be struck right away, but DO NOT agree only way out and we are screwed. UP FROM HERE.

0.70310.0000(0.00%)Jun 17 4:00 PMEDT